Samsung Electronics Shares Jump on HBM4 Mass Production Report 
SoftBank Shares Slide After Arm Earnings Miss Fuels Tech Stock Sell-Off 
Sony Q3 Profit Jumps on Gaming and Image Sensors, Full-Year Outlook Raised 
Prudential Financial Reports Higher Q4 Profit on Strong Underwriting and Investment Gains 
SpaceX Pivots Toward Moon City as Musk Reframes Long-Term Space Vision 
TrumpRx Website Launches to Offer Discounted Prescription Drugs for Cash-Paying Americans 
Once Upon a Farm Raises Nearly $198 Million in IPO, Valued at Over $724 Million 
Missouri Judge Dismisses Lawsuit Challenging Starbucks’ Diversity and Inclusion Policies 
Anta Sports Expands Global Footprint With Strategic Puma Stake 
Kroger Set to Name Former Walmart Executive Greg Foran as Next CEO 
Nvidia CEO Jensen Huang Says AI Investment Boom Is Just Beginning as NVDA Shares Surge 
FDA Targets Hims & Hers Over $49 Weight-Loss Pill, Raising Legal and Safety Concerns 
Weight-Loss Drug Ads Take Over the Super Bowl as Pharma Embraces Direct-to-Consumer Marketing 
OpenAI Expands Enterprise AI Strategy With Major Hiring Push Ahead of New Business Offering 
Global PC Makers Eye Chinese Memory Chip Suppliers Amid Ongoing Supply Crunch 
Washington Post Publisher Will Lewis Steps Down After Layoffs 
Taiwan Says Moving 40% of Semiconductor Production to the U.S. Is Impossible 
/AdlyxinTM) and iGlarLixi - EconoTimes)
- Royalty revenue of DKK 6.4 million / [Eur]0.9 million in Q2 2016 on Sanofi's sales of Lyxumia(r) (lixisenatide outside the U.S.)
- Recently, the U.S. FDA approved lixisenatide as AdlyxinTM to treat type 2 diabetes, and commercial launch by Sanofi in the U.S. is expected later in H2 2016
COPENHAGEN, Denmark, July 29, 2016 -- Zealand Pharma (Zealand), a biotechnology company, reports royalty revenue from Sanofi's global sales of Lyxumia(r) (lixisenatide outside the U.S.) of DKK 6.4 million / [Eur]0.9 million for the period from 1 April to 30 June 2016. For the first half of 2016, royalty revenue amounted to DKK 12.9 million / [Eur]1.7 million, a decrease of 3% compared to the same period in 2015. In its Q2 2016 earnings release today, Sanofi reported that sales of Lyxumia(r) were stable in H1 2016 versus the same period last year, measured at constant exchange rates.
Lixisenatide is a once-daily prandial GLP-1 receptor agonist for the treatment of patients with type 2 diabetes and was invented by Zealand. Global development and commercialization rights are licensed to Sanofi. Lixisenatide is approved under the proprietary name, Lyxumia(r), in more than 60 countries outside the U.S. and marketed by Sanofi in over 40 of these, including most EU countries (excluding France and Germany), Japan, Brazil, Mexico and India.
On 27 July 2016, lixisenatide was approved by the U.S. Food and Drug Administration (FDA) under the name of AdlyxinTM. U.S. commercial launch by Sanofi is expected later in H2 2016.
Sanofi has also developed iGlarLixi, a fixed-ratio combination of lixisenatide insulin glargine 100 Units/mL (Lantus(r)), its worldwide most-prescribed basal insulin, for the treatment of type 2 diabetes. iGlarLixi is undergoing regulatory review in both the U.S. and Europe. On May 25, an Advisory Committee of the FDA recommended the approval of iGlarLixi and a regulatory decision by the FDA is expected in August 2016. In Europe, a regulatory decision is expected in Q1 2017.
For further information, please contact:
Britt Meelby Jensen, President and Chief Executive Officer, Tel: +45 51 67 61 28, email: [email protected]
Hanne Leth Hillman, Senior Vice President, Investor Relations and Communications, Tel: +45 50 60 36 89, email: [email protected]
